Dual-qualified solicitor and Chartered Trade Mark Attorney, Chris Hoole, last month relocated to the Cambridge office of leading intellectual property firm Appleyard Lees.
Chris is looking forward to supporting existing and new clients in Cambridge, the UK and beyond, from his new home base.
Chris will continue his work to help build the national litigation and trade mark practices of Appleyard Lees, as the firm positions itself for further growth in years to come.
Laupheim, Germany; Milford, MA, USA and Cambridge, UK, 19 May 2020: Rentschler Biopharma SE, a world-class contract development and manufacturing organization (CDMO) for biopharmaceuticals, and Horizon Discovery, a global leader in the application of gene editing and gene modulation for cell line engineering, today announced the signing of a commercial license agreement.
We are excited to announce the launch of our new webinar series called BIODATAlks, taking the format of 30-45 minute interactive conversations, and hosted by the BioData Innovation Centre team at the Wellcome Genome Campus.
AMSBIO reports on the positive customer feedback received for their One-Step Luciferase Assay kit recently introduced for quantitation of firefly luciferase activity in mammalian cell culture.
In recent months, the world has faced its most significant peace-time crisis, effecting all corners of the globe. Like many others, we at PIR International have adopted new working practices to adapt and to continue to support our clients and candidates, who are developing lifesaving treatments and technologies for all diseases.
Westbury, NY – May 11, 2020 – BioIVT, a leading provider of research models and services for drug and diagnostic development, today announced that it is adding high-purity Kupffer cells to its portfolio of human primary hepatic cells to support liver disease drug discovery and development and help predict adverse drug reactions.
The Greenshoots Podcast by Appleyard Lees gives listeners access to insights from leading intellectual property specialists.
The bi-weekly programme delivers practical, timely guidance to innovators, inventors and IP owners and managers.
Leading IP specialists discuss the most important topics in patents, trade marks, IP litigation and IP strategy, in real time.
Cambridge, UK, 07 May 2020: IONTAS Limited (IONTAS), a leader in the discovery and optimisation of fully human antibodies, today announced it has entered into a collaboration agreement with Inotrem, a specialist in immunotherapy for acute and chronic inflammatory syndromes. As part of the agreement, IONTAS will apply its Mammalian Display technology to identify antibodies involved in the TREM-1 pathway.
AMSBIO has extended its COVID-19 research portfolio with the introduction of a service to provide custom lentivirus pseudotyped with spike glycoprotein from SARS-CoV-2 to help researchers identify potential targets for development of therapeutic drugs and vaccines.
Various research groups around the world have demonstrated that SARS-CoV-2 uses its spike glycoprotein S, a main target for neutralization antibody, to bind its receptor, and mediate membrane fusion and virus entry.